GET DAILY SIGNALSSpero Therapeutics (SPRO): Is a +420% Move to the $5.30 Target in Reach?
Key Takeaways
- The central target of $5.30 is the arithmetic mean of three verified analyst price targets—$4.00, $6.00, and $6.00—which average roughly $5.33 and are rounded to a clean level.
- The latest verified price of about $1.02 would need to rise roughly 420% to reach $5.30, a very large move for a clinical-stage biopharmaceutical.
- The analyst price target range is wide, from $4.00 to $6.00, reflecting genuine disagreement about the company's pipeline value.
- Supporting factors include a cash runway into 2028, royalty and milestone revenue from its tebipenem program, and a pivot toward a new immune-mediated disease asset.
- Principal risks include a stock down roughly 59% over the past year, mixed ratings that include a recent downgrade, and a small market capitalization of about $59 million.
- For additional detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- You can also explore Trending AI Robots for automated market-monitoring tools.
Analyst Price Targets and Consensus View
Spero Therapeutics, Inc. (SPRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company. Sell-side coverage is thin and sometimes inconsistent, so the targets below come from individual, attributable sources rather than aggregated consensus figures.
The most recent verifiable targets include $6.00 from Cantor Fitzgerald (analyst Kristen Kluska, who initiated with an Overweight rating in late October 2026) and $6.00 from H.C. Wainwright (maintained Buy and raised from $5.00 in September 2026). S&P Global data also lists a $4.00 target, creating a range of $4.00 to $6.00. The arithmetic mean of the three is approximately $5.33, which rounds to the $5.30 central target referenced here.
Opinion is split. Alongside the two Buy/Overweight ratings, Compass Point shifted to Neutral and Zacks to Hold in September 2026, while Wall Street Zen downgraded to Sell in late October 2026. Some platforms therefore display a “Hold” consensus even as published targets sit well above the current price.
Current Market Position and Path Toward the Target
SPRO shares closed near $1.02 in mid-November 2026, near the bottom of a 52-week range of roughly $0.96 to $3.08. Market capitalization stands at approximately $59 million, while the company reported about $50.8 million in cash and a net cash position near $48.7 million (roughly $0.84 per share). The gap to a $5.30 target implies an advance of about 420%, which would require a meaningful re-rating of the story rather than routine appreciation.
The stock has fallen about 59% over the past year and trades below both its 50-day and 200-day moving averages. For the target to become relevant, the market would need to shift from a cash-and-royalty focus toward a pipeline-option valuation.
What Could Support a Move Toward the Target
Financial support is clear: Spero reported about $47 million in trailing revenue and $7.4 million in net income, largely from licensing and milestone arrangements. Its lead asset, tebipenem HBr (licensed to GSK), has produced non-dilutive economics, including a $105 million royalty financing from HealthCare Royalty. Management has indicated cash is sufficient to fund operations into 2028.
Strategically, the company is shifting toward SP001, an anti-CD40L antibody in-licensed from Innovent and under development for IgG4-related disease, with Phase 2 work planned. Bulls contend the current price understates the value of net cash, royalty potential, and the new program’s optionality. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Prevent the Target From Being Reached
Clinical-stage programs carry high failure risk, and SP001 has yet to produce proof-of-concept in its new indication. Revenue depends on lumpy milestone and licensing payments, and some models project negative forward revenue growth. Shares outstanding have risen about 9% over the past year.
Sentiment remains mixed, with a recent Sell downgrade, Neutral and Hold ratings elsewhere, and the 59% year-over-year decline all pointing to institutional caution. A micro-cap trading near its 52-week low can stay detached from headline targets for extended periods.
Technical Levels and Market Structure
The 52-week low near $0.96 has served as a recent floor and remains a key support. Below that, durable support appears limited. On the upside, the 50-day moving average near $1.15 and the $1.15–$1.20 consolidation zone offer initial resistance, followed by the 200-day moving average near $1.93. Reaching $5.30 would require clearing these levels and returning to territory last seen before the 2026 decline.
Time Horizon and What Investors Should Monitor
Analyst targets typically reflect a roughly 12-month horizon, though specifics vary. The $4.00–$6.00 spread highlights differing assumptions about pipeline success. Key items to watch include quarterly results and guidance, SP001 Phase 2 updates, royalty or milestone payments, cash-burn trends, dilution, analyst revisions, and overall biotech sentiment.
Final Assessment
Can Spero Therapeutics (SPRO) reach $5.30? The rounded mean of three verified targets ranging from $4.00 to $6.00 implies a roughly 420% advance from about $1.02. The supporting case rests on net cash, royalty economics from the GSK-licensed tebipenem program, and optionality from the SP001 pivot. Countering that are a year-long downtrend, thin and divided coverage that includes a recent downgrade, and a pipeline still awaiting proof-of-concept. The next catalysts in earnings, pipeline updates, and analyst revisions will determine whether the gap narrows.
AI Daily Buy/Sell Signals
In my research process, I often turn to AI Daily Buy/Sell Signals from Tickeron. The tool uses artificial intelligence to monitor thousands of stocks and generate Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a volatile micro-cap like SPRO, where moves can be swift and sentiment-driven, it serves as a useful complement to fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRO sees its Stochastic Oscillator ascending out of oversold territory
On November 09, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 55 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 152 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SPRO entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.357) is normal, around the industry mean (3.498). P/E Ratio (7.357) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of resistant bacterial infections
Industry Biotechnology
Advertisement